Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Asc-type amino acid transporter 1 (Asc-1)
- Target
- Asc-1
- Molecular classification
- Transporter, Amino acid transporter, Heteromeric amino acid transporter (HAT) family, Solute carrier (SLC) family
01
Overview
Asc-type amino acid transporter 1 (Asc-1/SLC7A10) is a sodium-independent, small neutral amino acid transporter that functions as a heterodimeric complex with the heavy chain protein 4F2hc (SLC3A2). It is essential for the bidirectional transport of substrates such as D-serine, L-serine, glycine, and alanine, particularly in the central nervous system, where its activity determines the levels of glycine and D-serine, both critical for NMDA receptor function and neurological health. Loss of Asc-1 impairs neural homeostasis, leading to severe motor and developmental deficits. Although currently not widely targeted clinically, Asc-1 is under investigation as a potential therapeutic target and molecular imaging/probe tool for neurological diseases, owing to its central role in amino acid signaling and neurotransmission[4][5][8].
- Other names
- Asc-1SLC7A10Alanine-serine-cysteine transporter 1System ASC transporterASCT1ASC-1 transporter
02
Mechanism of action
Blockade or modulation of Asc-1 alters the extracellular and synaptic concentrations of glycine and D-serine, thereby impacting NMDA receptor activation and neural signaling
03
Biological functions
Mediates sodium-independent transport of small neutral amino acids (e.g., alanine, serine, glycine, and D-serine)Regulates neurotransmission, especially in the central nervous system, by maintaining levels of glycine and D-serine, key co-agonists at NMDA receptorsAmino acid exchange and homeostasis in excitable tissues and possibly other organs
04
Disease associations
Neurodevelopmental disorders and neurodegeneration (due to altered glycine and D-serine homeostasis affecting NMDA receptor function; Asc-1 knockout mice show tremors, ataxia, and seizures)Cancer (discussed for related SLC1A5 but not directly referenced for SLC7A10/Asc-1 in the above results)Other (potential, due to amino acid imbalance; broader pathology not fully defined)
05
Safety considerations
Disruption of Asc-1 function leads to severe neurological symptoms (tremor, ataxia, seizures, early death in animal models)Potential risk for cognitive or mood impairment via dysregulation of NMDA receptor co-agonists
06
Interacting drugs
No approved drugs are directly listed against Asc-1 in the above search results; specific pharmacological inhibitors and probes are under research
07
Biomarkers
D-serine and glycine levels in cerebrospinal fluid or brain regions could serve as pharmacodynamic biomarkers for Asc-1 modulation
Beyond the preview
Go deeper on Asc-type amino acid transporter 1 (Asc-1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asc-type amino acid transporter 1 (Asc-1).